Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) – HC Wainwright lowered their FY2026 EPS estimates for Trevi Therapeutics in a report issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.48) for the year, down from their prior estimate of ($0.47). HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.71) EPS and FY2029 earnings at ($0.15) EPS.
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11).
Check Out Our Latest Stock Analysis on Trevi Therapeutics
Trevi Therapeutics Stock Down 0.4%
Shares of NASDAQ:TRVI opened at $17.73 on Thursday. The company’s 50 day moving average price is $17.22 and its two-hundred day moving average price is $14.18. Trevi Therapeutics has a 12-month low of $6.93 and a 12-month high of $20.22. The firm has a market cap of $2.53 billion, a PE ratio of -52.15 and a beta of 1.03.
Institutional Investors Weigh In On Trevi Therapeutics
Large investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in Trevi Therapeutics in the second quarter valued at about $208,041,000. Deutsche Bank AG acquired a new position in Trevi Therapeutics during the second quarter worth about $2,135,000. Persistent Asset Partners Ltd bought a new position in shares of Trevi Therapeutics in the second quarter worth about $477,000. Flputnam Investment Management Co. bought a new position in shares of Trevi Therapeutics in the second quarter worth about $19,360,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Trevi Therapeutics in the 2nd quarter valued at approximately $5,720,000. Institutional investors and hedge funds own 95.76% of the company’s stock.
About Trevi Therapeutics
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.
Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.
Featured Articles
- Five stocks we like better than Trevi Therapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
